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Abstract Objective To evaluate the effect of different protocols of intratympanic dexamethasone injection in pa⁃
tients with unilateral sudden sensorineural hearing loss（SSNHL）who have failed to respond to typical medical treat⁃
ment（including systemic steroid treatment）. Methods From January 2005 to January 2008, 71 patients who were
diagnosed with unilateral SSNHL and failed typical medical treatment received intratympanic dexamethasone injec⁃
tion. Four injection protocols were employed: injection of 0.3 ml dexamethasone（5 mg／ml）three times a week for 3
weeks for a total dose of 13.5 mg（Group I, n=16）; injection of 0.6 ml (5 mg／ml）dexamethasone three times a week
for 3 weeks for a total dose of 27 mg（Group II, n=18）; injection at 0.3 ml（5 mg/ml）week for 6 weeks for a total dose
of 9 mg（Group III, n=18）; injection at 0.3 ml（5 mg／ml）／2 days for a total dose of 4.5 mg（Group IV n=19）.
Hearing recovery was assessed by pure tone audiogram. Results The total effective rate was 37.5%, 38.89%, 33.33%
and 36.84% for each treatment protocol, respectively, with no statistical difference between them（Ｐ> 0.05）. The re⁃
sults suggest that a total dose of 4.5 mg（injected once a week for 3 weeks）is the most adequate protocol, and in⁃
creasing dose or injection frequency yields no additional benefits. Conclusion Intratympanic dexamethasone signifi⁃
cantly improves the prognosis of SSNHL. Small dose at low injection frequency is sufficient. Further multicenter stud⁃
ies are needed to determine the standard treatment protocol.
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Introduction
Sudden sensorineural hearing loss（SSNHL）is a syn⁃
drome covering several heterogenous entities resulting
from different pathogenetic mechanisms. Research has
indicated that viral infection, microcirculation distur⁃
bance, and autoimmune disorder could be possible key
reasons for this hearing loss［1-6］. One generally accepted
treatment for SSNHL is systemic steroids, which can be
initiated prior to completion of studies such as magnetic
resonance imaging（MRI） and autoantibodies testing.
Steroids are believed to reduce inner ear inflammation
and autoimmune response and to be beneficial for recov⁃
ery of nerve function. Steroid receptors have been found
in the inner ear and may explain why steroid therapy is
effective. But for patients with diabetes, tumors, peptic
ulcers, tuberculosis, hypertension and other systemic
disorders, steroid therapy may not be appropriate. Intra⁃
tympanic steroids injection is a new treatment choice for
these patients, and may also offer alternatives for cases
that have failed to respond to typical medicine treat⁃
ments. The authors conducted a clinical study to deter⁃
mine therapeutic effects of different intratympanic dexa⁃
methasone injection protocols on sudden hearing loss,
in an attempt to determine an appropriate protocol to im⁃
prove our approach to SD.
Materials and methods
A prospective clinical study was conducted in 71 pa⁃
tients diagnosed with unilateral SSNHL of unknown
causes from January 2005 to January 2008, including
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27 males and 44 females, with a mean age of 44.46 years
（range 25-69 years）. All subjects satisfied the follow⁃
ing conditions: (1) idiopathic unilateral sensorineural
hearing loss, (2) no central nervous system disorders, (3)
within 1-7 days after the onset of hearing loss, (4) previ⁃
ously untreated, (5) normal hearing in the opposite ear
for age, and (6) unresponsive to a 10 day course of typi⁃
cal systemic medicine treatment including intravenous
steroids, vasodilator, low-molecular-weight dextran,
oral Ca2 + channel blocker, hyperbaric oxygen. All pa⁃
tients gave a complete clinical history, underwent physi⁃
cal and audiologic examination, and received testing for
syphilis and autoimmune antibodies. Magnetic reso⁃
nance imaging（MRI）was negative in these patients. In⁃
formed consent was obtained from each patients for par⁃
ticipation in the study，and study protocols were ap⁃
proved by the hospitals Ethics Committee.
The criteria of diagnosis and treatment effect classifi⁃
cation for SSNHL published by Chinese Medical Associ⁃
ation in 1997［7］ were adopted for this study. Pure-tone
average（PTA）was calculated as the average of thresh⁃
olds at 0.25, 0.5, 1, 2 and 4 kHz.
Severity of hearing loss was graded as: Mild:（26-40
dB）, Moderate: （41-55 dB）, Moderately severe:
（56-70 dB）, Severe:（71-90 dB）and Profound:（>90
dB）.
The extent of hearing recovery was reported as Com⁃
plete Recovery（R）-PTA in normal limits or at pre-ill⁃
ness level; Marked Recovery（MR）-PTA improve⁃
ment ≥30 dB; Partial Recovery（PR）-PTA improve⁃
ment 15 to 30 dB; And Unchanged（U）-PTA improve⁃
ment≤ 15 dB
Dexamethasone was delivered via a pressure equaliza⁃
tion tube across the tympanic membrane, followed by
fixed head position for 15 minutes to allow maximal ex⁃
posure of the steroid to the round window.
A total of 71 cases were randomly selected to receive
one of the four dexamethasone（5 mg／ml）dosing proto⁃
cols: injection of 0.3 ml three times a week for 3 weeks
for a total dose of 13.5 mg（Group Ⅰ, n=16）; injection
of 0.6 ml three times a week for 3 weeks for a total dose
of 27 mg（Group Ⅱ, n=18）; injection at 0.3 ml／week
for 6 weeks for a total dose of 9 mg（Group IIⅡ, n=18）;
injection at 0.3 ml/2 days for a total of 3 injections and
a total dose of 4.5 mg（Group Ⅳ n=19）. Patient profiles
and therapeutic effects were compared among the 4
groups.
Statistical analysis：
The mean age, average time from onset to treatment,
and degree of hearing loss were analyzed by means of
T-test. Treatment effects were analyzed by means of χ2
test. P< 0.05 was considered significant.
Results
Characteristics
Gender（F／M,）
Mean age（years）
Sick ear（L／R,）
Grades of hearing loss（PTA）
Mild
Moderate
Moderately severe
Severe
Profound
Cases of moderately severe and severe/profound hearing
loss（n,%)
Interval from the onset(days)
GroupⅠ（n=16）
10／6
45.31
12/4
3
4
7
2
0
9（52.25%）
4.13
GroupⅡ（n=18）
13／5
41.06
7/11
5
3
8
1
1
10（55.56%）
3.72
GroupⅢ（n=18）
10／8
47.33
9/9
2
5
7
2
2
11（61.11%）
3.83
GroupⅣ（n=19）
11／8
44.26
5/14
5
5
8
1
2
11（57.89%）
4.26
Table.1 Basic informations of the four groups
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Groups
Ⅰ
Ⅱ
Ⅲ
Ⅳ
Total
Recovery（n）
1
1
2
Marked recovery（n）
2
2
3
7
Partial recovery（n）
3
5
4
3
15
Unchanged（n）
10
11
12
12
45
Effective rate（%）
37.5*
38.89*
33.33*
36.84*
34.78
Table.2 Therapeutic effect of four groups
*：The effective rate was not statistically different between the four groups.（P>0.05）
The mean age, average time from onset to treatment,
and degree of hearing loss were not statistically different
between the four groups（P> 0.05）（table1）.
The effective rate was 37.5% , 38.89% , 33.33% and
36.84%, respectively, and not statistically different be⁃
tween the four groups（P> 0.05）（table 2）.
Two patients declined further consultation. The total
effective rate was 34.78%. Other than the expected tym⁃
panic membrane perforation and nausea following injec⁃
tion, there were no other serious unexpected adverse
events. No increase in dizziness or tinnitus lasting lon⁃
ger than 24 hours were observed after injections. Dis⁃
cussion
It is generally acknowledged that the two important
factors that influence the prognosis include the duration
of hearing loss before seeking treatment, and the extent
of hearing loss. In this study, patient age, interval from
hearing loss onset to treatment and severity of hearing
loss were not different between the four groups, making
comparison of therapeutic effects relatively straightfor⁃
ward.
Treatment of SSNHL remains controversial. Different
approaches such as steroids, vasodilator, antiviral
agents, diuretics, and low-salt diets have been suggest⁃
ed. As a result of its anti-inflammatory and immunosup⁃
pressive effects, high-dose systemic steroid therapy is
currently the mainstay of treatment for SSNHL［8-10］. Re⁃
current SSNHL is sensitive to transtympanic and system⁃
ic steroid treatment［11］. Animal studies have found that
intratympanic steroid injections, introducing steroids
through the tympanic membrane, results in reduced sys⁃
temic steroid toxicity and higher perilymph steroid level
selectively. Past research has focused on effecacy of in⁃
tratympanic steroid injections compared with other ap⁃
proaches. Few controlled studies have been published
regarding the appropriateness of protocols of this thera⁃
py［12］.
Intratympanic steroid therapy is administered to the
round window niche／membrane in the middle ear to
target the inner ear. There is little systemic absorption,
which makes it ideal for patients unable to take system⁃
ic steroids. In addition, intratympanic steroid injection
provides a higher concentration of steroid to the end or⁃
gan，which may be most beneficial as primary therapy in
patients unable to take systemic steroid therapy. The
route of intratympanic delivery is usually via injection
through the tympanic membrane, or drops instilled
through pharyngotympanic tube. The former is a trau⁃
matic mode, and tympanic membrane perforation, verti⁃
go, nausea and pain after injection may be the expected
adverse effects. The latter is relatively nontraumatic,
but cannot be applied to patients with rhinopharyngitis
or eustachian tube dysfunction. All patients are request⁃
ed to keep their heads in a specified position for 15 to
20 minutes to allow maximal exposure of the steroid to
the round window. Unfortunately, there is no consensus
on a“standard”protocol for intratympanic steroid thera⁃
py. In our study, the effective rate was not statistically
different between the four tested treatment protocols,
suggesting that different combination of dose, therapeu⁃
tic frequency and duration do not influence treatment
efficacy in SSNHL. A total dose of 4.5 mg (1.5 mg/injec⁃
tion/week for 3 weeks) may be satisfactory.
An important factor of therapy is to initiate systemic
steroids as early as possible. The highest rate of recov⁃
ery has been found in patients who are started within
2 - 4 weeks of onset of hearing loss.
Conclusions
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This study shows that, as an effective and safe thera⁃
py, intratympanic dexamethasone significantly improves
the prognosis in SSNHL that has failed intravenous or
oral steroid treatment, consistent with previously re⁃
ports. Further more, the results show that a total dose of
4.5 mg, administered at 1.5 mg／injection／week for 3
weeks, is sufficient and increasing dosage or injection
frequency offers no additional benefits. Understandably,
further multicenter studies are needed to determine the
standard protocol.
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